Abcam, ab32152, Anti-VEGF Receptor 1 antibody [Y103]

Size: 20µL / 100µL / 1mL
Anti-VEGF Receptor 1 antibody [Y103] (ab32152) is a rabbit monoclonal antibody detecting VEGF Receptor 1 in Western Blot, IP, IHC-P . Suitable for Chinese hamster, Human, Mouse, Rat . - Biophysical QC for unrivalled batch-batch consistency - Over 300 publications - Trusted since 2006
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:Y103,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Human, Chinese hamster, Rat,
Applications:IHC-P, IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:Based on our results, no splice isoforms can be detected.

Product details:
Product Specifications
Anti-VEGF Receptor 1 antibody [Y103] (ab32152) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-P, IP, WB in hamster, human, mouse, rat samples.
Anti-VEGF Receptor 1 antibody [Y103] (ab32152) specifically detects VEGF Receptor 1 (UniProt ID: P17948; Molecular weight: 148kDa) and is sold in 100 µL and 1 mL selling sizes.
Quality and Validation
Abcam's high quality manufacturing and validation processes ensure Anti-VEGF Receptor 1 antibody [Y103] (ab32152) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
Anti-VEGF Receptor 1 antibody [Y103] (ab32152) has been cited over 308 times in peer reviewed journals and is trusted by the scientific community.
Anti-VEGF Receptor 1 antibody [Y103] (ab32152) has 21 independent reviews from customers.
Related Products
Antibody clone Y103 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 488, Alexa Fluor® 555, Alexa Fluor® 647, Alexa Fluor® 594, Alexa Fluor® 568, Alexa Fluor® 750 (
ab309078
ab309079
ab309080
ab311783
ab313064
ab321585
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
VEGF Receptor 1 also known as FLT-1 is a protein that plays a critical role in the regulation of angiogenesis. Its mass is approximately 180 kDa. FLT-1 is a receptor tyrosine kinase expressed mainly on the surface of endothelial cells but also in monocytes and macrophages. The receptor binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) which initiates a series of signaling cascades important for vascular development and function.
Biological function summary
FLT-1 mediates important cellular responses such as cell migration and proliferation. Although it often functions in conjunction with other receptors like VEGFR-2 FLT-1 has unique binding affinities that modulate the availability of VEGF for other receptors. FLT-1 proteins as part of complex signaling networks actively contribute to maintaining vascular homeostasis and regulating blood vessel permeability.
Pathways
FLT-1 is an important component in the VEGF signaling pathway and also part of the PlGF/VEGF pathway. The receptor serves as a decoy to regulate the amount of VEGF interaction with VEGFR-2 influencing endothelial cell function and vascular permeability. By sequestering VEGF FLT-1 helps maintain the balance in this angiogenic signaling network interacting with proteins like VEGF PlGF and the anti-VEGF agents that target these pathways.
FLT-1 is implicated in cancer and diabetic retinopathy. Overexpression or dysregulation of FLT-1 can contribute to tumor angiogenesis which can enhance tumor growth and metastasis. In diabetic retinopathy abnormal FLT-1 activity affects retinal blood vessels leading to vision impairment. Similar interactions involve VEGFR-2 and other downstream effectors emphasizing the potential of FLT-1 as a therapeutic target for conditions associated with excessive angiogenesis and vascular dysfunction.